Assessing Drug Performance in RCC Therapy Area – Borderless Access Study

RCC Therapy Area

Business Problem

A pharma major turned to Borderless Access to get insights into awareness, perception and behavior of oncologists in the USA region for strategic business decisions in the Renal Cell Carcinoma therapy area.

What & how we did

We took a look at the current & future therapy usage in the neoadjuvant & metastatic setting, analyzed the product attributes which are driving prescription patterns and measured the level of awareness about the new agents in development. We assessed the attitude & perception with respect to targeted therapies and angiogenesis inhibitors in RCC treatment.

Key insights

Through our study, we were able to compile a list of influencing drivers for brand prescription, analyze brand awareness and willingness to prescribe brands for 1st line treatment versus 2nd line treatment, measure brand awareness vs brand usage and generate real-time prescription insights on brand commitment vs prescription behavior.

Client Impact :

The client was able to get a comprehensive view of the brand recognition and familiarity among targeted physicians and their level of drug usage, attitude and perceptions. The insights shaped the targeted messages driving effective brand impact.

Market

France

Germany

Italy

UK

Spain